Krabbe Disease Epidemiology Forecast 2025-2034

Krabbe disease has an estimated global incidence of approximately 1 in 100,000 live births, though rates vary significantly by region and population. The Krabbe disease epidemiology forecast by Expert Market Research indicates that no significant sex predilection is observed, as males and females are affected equally. The disease affects individuals of all ethnic backgrounds but is more frequently reported in populations with known founder mutations.

Krabbe Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Krabbe Disease Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Krabbe disease. It projects the future incidence and prevalence rates of Krabbe disease cases across various populations. The study covers age, gender, and type as major determinants of the Krabbe disease population. The report highlights patterns in the prevalence of Krabbe disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Krabbe disease epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Krabbe Disease Understanding: Disease Overview

Krabbe disease, or globoid cell leukodystrophy, is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the GALC gene, resulting in galactocerebrosidase deficiency. This enzyme deficiency leads to accumulation of psychosine, causing progressive demyelination in the central and peripheral nervous systems. The disease presents in infantile, late-infantile, juvenile, or adult forms, with the infantile form being the most severe. The symptoms include irritability, feeding difficulties, spasticity, developmental regression, and vision loss. Diagnosis is confirmed through enzyme assays and genetic testing. Hematopoietic stem cell transplantation is the only disease-modifying therapy available when performed early.

Krabbe Disease Epidemiology Perspective

The Krabbe disease epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Krabbe Disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Krabbe disease and their trends. The Krabbe disease detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Early-infantile form accounts for 85-90% of cases, presenting within the first 6 months; juvenile and adult forms occur later.
• Krabbe disease is an autosomal recessive disorder, affecting both males and females equally.
• Higher incidences have been reported in certain isolated or high-consanguinity populations, such as the Druze community in Israel (up to 6 per 1,000 births) and some Scandinavian, Mexican, and Puerto Rican populations.

Country-wise Krabbe Disease Epidemiology Segment

The Krabbe disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, Krabbe disease is a rare lysosomal storage disorder with an estimated prevalence of 1 in 250,000 individuals. Data from the U.S. Health Resources and Services Administration (HRSA) indicate that approximately 40 babies are born each year with Krabbe disease, including 11 cases of the infantile subtype. A retrospective analysis reported a birth incidence of 1 in 310,000 live births across U.S. hospitals, underscoring its significant yet rare clinical impact.

Krabbe Disease: Treatment Overview

Krabbe disease treatment focuses on slowing disease progression and managing symptoms, as no curative therapy currently exists. Hematopoietic stem cell transplantation (HSCT), when performed pre-symptomatically, can delay neurological decline in infantile-onset cases. Supportive care includes anticonvulsants, physiotherapy, occupational therapy, and nutritional support to maintain quality of life. Advances in gene therapy, enzyme replacement, and substrate reduction therapies are under investigation and show promising preclinical results. Early newborn screening and diagnosis remain crucial for improving treatment outcomes and extending survival in affected infants.

Key Questions Answered

• What are the key findings of Krabbe disease epidemiology in the 8 major markets?
• What will be the total number of patients with Krabbe disease across the 8 major markets during the forecast period?
• What was the country-wise Krabbe disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of Krabbe disease during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Krabbe disease during the forecast period of 2025-2034?
• What are the currently available treatments for Krabbe disease?
• What are the disease risks, signs, symptoms, and unmet needs of Krabbe disease?

Scope of the Krabbe Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Krabbe disease based on several factors.
• Krabbe Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Krabbe disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.